Positive Topline Results for Investigational MS DrugPositive Topline Results for Investigational MS Drug

Two phase 3 studies suggest the investigational drug ocrelizumab was superior to interferon beta-1a in reducing the relapse rate in patients with relapsing multiple sclerosis. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news